CL2025003893A1 - Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides - Google Patents

Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides

Info

Publication number
CL2025003893A1
CL2025003893A1 CL2025003893A CL2025003893A CL2025003893A1 CL 2025003893 A1 CL2025003893 A1 CL 2025003893A1 CL 2025003893 A CL2025003893 A CL 2025003893A CL 2025003893 A CL2025003893 A CL 2025003893A CL 2025003893 A1 CL2025003893 A1 CL 2025003893A1
Authority
CL
Chile
Prior art keywords
monoclonal antibody
binds
types
amyloid fibrils
amyloid
Prior art date
Application number
CL2025003893A
Other languages
English (en)
Spanish (es)
Inventor
Brian Pepys Mark
Langley David
Jackson Jennifer
William Wade Jack
Christ Daniel
Henry Jake
Original Assignee
Immutrin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Application filed by Immutrin Ltd filed Critical Immutrin Ltd
Publication of CL2025003893A1 publication Critical patent/CL2025003893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2025003893A 2023-06-14 2025-12-11 Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides CL2025003893A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies

Publications (1)

Publication Number Publication Date
CL2025003893A1 true CL2025003893A1 (es) 2026-01-30

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003893A CL2025003893A1 (es) 2023-06-14 2025-12-11 Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides

Country Status (7)

Country Link
KR (1) KR20260026033A (fr)
CN (1) CN121487964A (fr)
AU (1) AU2024304161A1 (fr)
CL (1) CL2025003893A1 (fr)
IL (1) IL325202A (fr)
MX (1) MX2025014924A (fr)
WO (1) WO2024256583A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
WO1992003917A1 (fr) 1990-08-29 1992-03-19 Genpharm International Recombinaison homologue dans des cellules de mammiferes
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
WO2015092077A1 (fr) * 2013-12-20 2015-06-25 Neurimmune Holding Ag Thérapie de l'amyloïdose de la transthyrétine (ttr) à base d'anticorps, et anticorps d'origine humaine afférents
JP6818268B2 (ja) * 2014-01-29 2021-01-20 Ｋｍバイオロジクス株式会社 抗トランスサイレチンヒト化抗体
MX2020003041A (es) * 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法

Also Published As

Publication number Publication date
IL325202A (en) 2026-02-01
CN121487964A (zh) 2026-02-06
KR20260026033A (ko) 2026-02-25
AU2024304161A1 (en) 2025-12-11
WO2024256583A1 (fr) 2024-12-19
MX2025014924A (es) 2026-02-03

Similar Documents

Publication Publication Date Title
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
EP1425042A4 (fr) Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b
CL2022002670A1 (es) Anticuerpos contra amiloide-bcon piroglutamato y usos de estos (divisional solicitud 202102473).
MA49038B1 (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
EA202192260A1 (ru) Биомаркеры циклин-зависимой киназы 2 и их применение
SA520411577B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA202191185A1 (ru) Способы ингибирования ангиогенеза у пациента
JP2013231045A5 (fr)
PE20081264A1 (es) Anticuerpos agonistas anti-notch3
EA201290525A1 (ru) Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
CR10297A (es) "metodos para prevenir y tratar efermedades amiloidogenicas"
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
ECSP099656A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
GEAP202215170A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
MX2023002496A (es) Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.
MX2020011823A (es) Metodos para tratar cancer con combinacion de anticuerpo anti-muerte programada-1 (pd-1) y conjugado de anticuerpo anti-factor de tejido y farmaco.
MX2021004045A (es) Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.